Trial to Determine the Maximum Tolerated Dose of Genexol-PM Plus Gemcitabine and Evaluate Efficacy and Safety of Genexol-PM Regimens in Subjects With Advanced Pancreatic Cancer
Phase of Trial: Phase I/II
Latest Information Update: 10 May 2017
At a glance
- Drugs Paclitaxel (Primary) ; Gemcitabine
- Indications Pancreatic cancer
- Focus Adverse reactions
- Sponsors Samyang Biopharmaceuticals Corporation
- 28 May 2013 Data was published for the 2013 Annual Meeting of the American Society of Clinical Oncology (ASCO) and chosen for inclusion online in the ASCO 2013 Annual Meeting Proceedings, according to a Sorrento Therapeutics media release.
- 13 May 2013 Status changed from active, no longer recruiting to completed, based on information in a Sorrento Therapeutics and IgDraSol media release.
- 28 Apr 2009 New trial record